Raymond James & Associates Eton Pharmaceuticals, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Eton Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 10,250 shares of ETON stock, worth $201,515. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,250
Previous 10,250
-0.0%
Holding current value
$201,515
Previous $33,000
84.85%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ETON
# of Institutions
87Shares Held
15MCall Options Held
242KPut Options Held
11.8K-
Opaleye Management Inc. Boston, MA2.86MShares$56.2 Million9.75% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA2.03MShares$39.9 Million2.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.31MShares$25.8 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.18MShares$23.1 Million0.73% of portfolio
-
Geode Capital Management, LLC Boston, MA593KShares$11.7 Million0.0% of portfolio
About Eton Pharmaceuticals, Inc.
- Ticker ETON
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,297,000
- Market Cap $497M
- Description
- Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for th...